Editas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10 – P&T Community
|
Editas Medicine Receives EMA's Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10
P&T Community 26, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the European Medicines Agency (EMA) granted Orphan Medicinal Product designation to EDIT-101, a pre-clinical, CRISPR-based … Editas Medicine, Inc. (NASDAQ:EDIT) Closed Higher Than Its 50 Day Average |
